Exploring novel drug targets for erectile dysfunction through plasma proteome with genome

Area of Science:

• Genetics
• Pharmacology
• Urology

Background:

• Erectile dysfunction (ED) presents significant challenges in current treatment and prevention strategies.
• Identifying novel therapeutic targets is crucial for advancing ED management.

Purpose of the Study:

• To conduct a genome-wide Mendelian randomization (MR) analysis to identify druggable therapeutic targets for ED.
• To investigate the causal effects of plasma proteins on ED and validate potential drug targets.

Main Methods:

• Proteome-wide MR and summary data-based MR (SMR) analyses were performed to identify causal associations between plasma proteins and ED.
• Enrichment analysis, protein-protein interaction (PPI) networks, drug prediction, and molecular docking were used for target validation.
• Systematic MR assessed lifestyle and disease factors associated with identified targets.

Main Results:

• 126 genetically predicted plasma proteins showed a causal association with ED.
• TMEM9 was linked to increased ED risk, while MDH1, NQO1, QDPR, ARL4D, TAGLN2, and PPP1R14A were linked to decreased risk.
• Identified targets are involved in metabolic and redox processes; molecular docking confirmed drug-binding potential.

Conclusions:

• Seven plasma proteins (MDH1, NQO1, QDPR, ARL4D, TAGLN2, TMEM9) were identified as causally associated with ED.
• These proteins can be modulated by lifestyle and disease factors, offering insights for prevention and treatment.
• The study provides novel insights into ED etiology and potential therapeutic targets, aiding drug development.